Mill Valley, CA, United States of America

Alejandro Dorenbaum

USPTO Granted Patents = 10 (Patent Applications = 10)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 3.3

ph-index = 7

Forward Citations = 85(Granted Patents)

Company Filing History:

7 out of 135

Biomarin Pharmaceutical Inc.

patents

3 out of 4

Mirum Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11918578 - Methods for treating cholestasis (2024-03-05),

2. 11497745 - Methods for treating cholestasis (2022-11-15),

3. 11229647 - Methods for treating cholestasis (2022-01-25),

4. 9993481 - Methods and compositions for the treatment of metabolic disorders (2018-06-12),

5. 9433624 - Methods and compositions for the treatment of metabolic disorders (2016-09-06),

6. RE43797 - Methods of administering tetrahydrobiopterin (2012-11-05),

7. 8067416 - Methods and compositions for the treatment of metabolic disorders (2011-11-29),

8. 7947681 - Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring (2011-05-24),

9. 7612073 - Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring (2009-11-03),

10. 7566714 - Methods and compositions for the treatment of metabolic disorders (2009-07-28),

Title: Alejandro Dorenbaum: Innovator in Cholestasis Treatment

Introduction

Alejandro Dorenbaum is a prominent inventor based in Mill Valley, CA (US). He has made significant contributions to the field of medicine, particularly in the treatment of liver diseases. With a total of 10 patents to his name, Dorenbaum's work has the potential to impact many lives.

Latest Patents

Dorenbaum's latest patents focus on innovative methods for treating cholestasis. These methods involve administering an Apical Sodium-dependent Bile Acid Transporter (ASBTI) to subjects suffering from liver disease. Specifically, the invention details administering an ASBTI at a dose of at least 10 μg/kg/day to effectively treat cholestasis.

Career Highlights

Throughout his career, Dorenbaum has worked with notable companies such as BioMarin Pharmaceutical Inc. and Mirum Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative approaches to medical treatment.

Collaborations

Dorenbaum has collaborated with esteemed colleagues, including Daniel I Oppenheimer and Emil D Kakkis. These partnerships have further enhanced his research and development efforts in the medical field.

Conclusion

Alejandro Dorenbaum is a dedicated inventor whose work in treating cholestasis showcases his commitment to advancing medical science. His innovative methods and collaborations highlight the importance of teamwork in achieving breakthroughs in healthcare.

This text is generated by artificial intelligence and may not be accurate.